Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06771505
Recruiting Observational

SBS DISK- Creation of a Quality of Life Tool for Short Bowel Patients Compared With a Validated Quality of Life Questionnaire (SBS QoL)

NCT06771505 · tracked via the Priya Life Science France tracker
Sponsor
Hospices Civils de Lyon
Phase
Observational
Started
2025-01-15
Last updated
2026-02-12

Condition(s) studied

Short Bowel Syndrome

Study summary

Patients with short bowel syndrome have an impact on their quality of life because they need temporary or permanent parenteral nutritional support. The quality of life of these patients has been the subject of several studies and assessment tools exist, such as the Short Bowel Syndrome Quality of Life (SBS QoL). This tool may seem complex and tedious to use in everyday practice. However, it is important to regularly assess the quality of life of these patients. This is why the investigators are proposing to create a new tool for more rapid assessment of the quality of life of patients with short bowel syndrome.

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18 or over * Patient able to read and speak French * Patient suffering from short bowel syndrome Exclusion Criteria: * Known cognitive disorders

Primary outcome measure(s)

  • Validation of a new quality of life tool, the SBS disk, in comparison with a quality of life assessment tool, the SBS QoL. — Day 1
    Self-questionnaire in the form of a disk which covers 10 themes: Energy, stress level, anxiety, diet, abdominal pain, transit, appliances, social life, social and professional activity, sleep, as well as self-image and intimate life, according to the recommendations of the WHO quality of life assessment. These themes are the same as those generally covered by the SBS QoL reference questionnaire, with the exception of self-image and intimacy. The themes are evaluated according to the patient's feelings during the past week on a scale from 0 to 10.

Trial sites (1)

FacilityCityRegionStatus
Hôpital Lyon Sud - CHLS Pierre-Bénite France Recruiting

More Hospices Civils de Lyon trials in France

Non-invasive Personalized Transcranial Cortical Neurostimulation for Pain Relief Recruiting
Validation of the French Version of the New Mobility Score (NMS) Recruiting
Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts Recruiting
Impact of Mental Health First Aid-trained Peers on the Mental Well-being of First-year Medical Residents. Active, not recruiting
Psychological Support Interventions for Women With Endometriosis (ENDOPSY) Starting soon

Other trials for the same condition

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. Active, not recruiting
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS Recruiting
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06771505 on ClinicalTrials.gov ↗ ← All trials in France